Olopatadine - Mechanism of Action, Indications, Dosage, and Adverse Drug Reactions

Overview

Olopatadine is an antihistamine that works by preventing the effects of histamine, thereby helping to cure allergic diseases, such as allergic conjunctivitis (eye irritation). It is used as a symptomatic treatment for ocular itching brought on by allergic conjunctivitis and irritation or redness of the eyes brought on by ragweed, grass, pollen, animal dander, or hair. Olopatadine has a dual mechanism of action. It stabilizes mast cells and also inhibits histamine H1 receptors. On December 18, 1996, the Food and Drug Administration (FDA) authorized Olopatadine 0.1 percent ophthalmic solution to treat allergic conjunctivitis symptoms, such as redness and itching.

Drug Group

Olopatadine is a member of the class of antihistamines. It works by stopping the body's production of histamine, which causes allergies (an abnormal immune reaction to foreign substances like pollen). Antihistamines are frequently used to treat allergy-related symptoms, such as hives, runny nose, sneezing, and itching.

Indications

A mast cell stabilizer called Olopatadine solution is prescribed to relieve ocular irritation brought on by allergic conjunctivitis.

Dosage Forms and Available Strengths

Olopatadine is available as a 0.2 percent ophthalmic solution (2.22 mg or milligrams of Olopatadine hydrochloride are contained in each milliliter).

Warnings and Precautions

1. Topical Use: Olopatadine hydrochloride ophthalmic solution of 0.2 percent is intended for topical ocular use only.

2. Tip and Solution Contamination: As with any eye drop, caution should be exercised to avoid touching the eyelids or surrounding areas with the dropper tip of the container to avoid contaminating the dropper tip and solution. When the bottle is not in use, keep it tightly closed.

3. Using Contact Lenses:

• It is best to encourage patients not to wear contact lenses if they have red eyes.

• It is not recommended to use Olopatadine hydrochloride ophthalmic solution of 0.2 percent to relieve irritation caused by contact lenses.

• Soft contact lenses can absorb Benzalkonium chloride, the preservative found in Olopatadine ophthalmic solution. Patients wearing soft contact lenses who do not have red eyes should be encouraged to rest for a minimum of 10 minutes before placing their contact lenses. Olopatadine hydrochloride ophthalmic solution of 0.2 percent should be administered first.

For Patients

What Is Allergic Conjunctivitis?

The inflammation known as allergic conjunctivitis affects the conjunctiva, which is the tissue that covers the white portion of the eyeball and the insides of the eyelids. An allergic reaction to dust, mold spores, pollen, animal dander, and some chemicals brings it on. Some symptoms include swollen eyelids, a burning sensation, grittiness, red, itchy, and watery eyes. Acute (sudden onset) allergic conjunctivitis is more common during allergy season and is short-term. Chronic (long-standing) allergic conjunctivitis, on the other hand, can occur year-round and is caused by indoor allergens.

How Does Olopatadine Work?

Olopatadine eye drops can be utilized to treat itchy eyes brought on by allergic conjunctivitis because they stabilize mast cells and have antihistamine qualities, which help relieve the condition's symptoms, including watery, itchy eyes. By stabilizing mast cells and preventing the release of histamine, Olopatadine functions as a selective antagonist of the histamine H1 receptor. Histamine's effects diminish when these receptors are inhibited, which lessens allergy symptoms.

What Are the Benefits of Olopatadine?

Olopatadine is a second-generation antihistamine with several advantages, especially for treating allergic reactions.

• Effective Allergic Symptom Relief: Olopatadine's effectiveness in treating allergy symptoms is well known. It relieves allergic reactions like itching, redness, and swelling.

• Management of Allergic Conjunctivitis: Olopatadine eye drops address the indications and manifestations of seasonal allergic conjunctivitis. They relieve allergic conjunctivitis's burning, itching, redness, and watering of the eyes.

• Treatment of Allergic Rhinitis: Olopatadine in nasal spray form is used to treat allergy symptoms such as congestion, runny or stuffy nose, and sneezing.

• Less Likely to Cause Drowsiness: Olopatadine is substantially less likely to cause drowsiness than other comparable medications.

• Enhances Quality of Life: Due to discomfort and suffering, allergies can significantly negatively influence an individual's quality of life. On the other hand, Olopatadine is very successful in relieving these symptoms.

How Is Olopatadine Administered?

The affected eye(s) is commonly treated with nonprescription ophthalmic Olopatadine 0.1 percent twice a day, and nonprescription ophthalmic Olopatadine 0.2 percent once a day. Olopatadine should be taken at roughly the same time(s) each day. Use Olopatadine precisely as prescribed.

To administer the eye drops, take the following actions:

• Hands should be well cleaned with soap and water before using Olopatadine eye drops.

• Make sure there are no breaks or chips in the dropper tip.

• Avoid touching the eye drops or droppers, and keep them clean.

• Pull down the eyelid and tilt the head back to form a pocket.

• Without touching the eye, bring the dropper up close to it. Squeeze the dropper gently while pressing the remaining fingers up on the face. For two to three minutes, close the eyes and incline the head downward; do not squeeze or squint the eyes.

• Place a fingertip gently up against the tear duct. Using a tissue, wipe away any excess liquid from the face.

• Do not clean or rinse the dropper bottle's tip; replace and secure the cap.

• Hand wash to get rid of medication traces.

• Wait at least five minutes before taking another eye medication after using Olopatadine eye drops.

What Are the Side Effects of Olopatadine?

Olopatadine might have unfavorable effects. If any of these Olopatadine symptoms are severe or persistent, let the physician know:

• Blurred vision.

• Dry eyes that hurt, burn, or become red.

• Taste varies.

• Unusual feeling in the eyes.

Certain adverse effects of Olopatadine may be severe. Call the doctor right away and cease taking Olopatadine if people encounter any of the following symptoms:

• Vision changes.

• Eye pain.

• Itching in the eyes that gets worse or lasts longer than three days after starting treatment.

Olapatadine may result in additional adverse effects. If people have any odd side effects while taking Olopatadine, contact the doctor.

What Are the Things to Inform the Doctor Before Taking Olopatadine?

• Inform the doctor and pharmacist if people have allergies to Benzalkonium chloride, Olopatadine, or any other medications before using Olopatadine eye drops.

• Inform the physician and pharmacist about the vitamins, nutritional supplements, herbal items, prescription and over-the-counter (OTC) drugs, and vitamins people use.

• Inform the physician if people are nursing a baby, intend to get pregnant, or are already pregnant. Contact the physician if people become pregnant while taking Olopatadine.

• People should be aware that if one or more of their eyes are red, they should not wear contact lenses. If they wear contact lenses and the eye is not red, they should be aware that soft contact lenses can absorb the Benzalkonium chloride found in the Olopatadine solution. When using nonprescription ophthalmic Olopatadine eye drops, they should be removed first and replaced after 10 minutes.

Dietary Considerations:

Olopatadine ophthalmic solution does not require any changes to the diet.

Missed Dose:

When an Olopatadine ophthalmic solution dose is missed, inject it immediately. However, if the following dose is close to time, skip it and avoid giving oneself two doses of Olopatadine ophthalmic solution to make up for the missing ones.

Overdose:

Olopatadine ophthalmic overdose is not detrimental, but if swallowed, seek emergency medical care or contact the poison helpline.

Storage and Handling:

Olopatadine hydrochloride ophthalmic solution is packaged in dropper-tipped bottles, stored at 25 to 32 degrees Celsius (77 to 89.6 degrees Fahrenheit), and in high-up places, making it inaccessible to children.

Disposal:

Use an FDA take-back program to appropriately dispose of any unnecessary Olopatadine medicines; inquire with the pharmacist or the local recycling department about these programs. Do not flush Olopatadine drugs down the toilet.

For Doctors

Dosing

• The recommended adult dosage for seasonal allergic conjunctivitis is 0.1 percent Olopatadine solution, applied one drop in each affected eye twice daily at six to eight hours intervals, or 0.2 or 0.7 percent solution, applied once daily.

• For children two years of age and older, the recommended dosage for seasonal allergic conjunctivitis is 0.2 or 0.7 percent Olopatadine solution given once daily to each afflicted eye; for children three years of age and older, the recommended dosage is 0.1 percent solution applied twice daily at intervals of six to eight hours.

What Are the Pharmacological Aspects of Olopatadine Ophthalmic Solution?

• Pharmacodynamics: Olopatadine is an anti-allergenic chemical that reduces inflammation and allergy symptoms at different sites by inhibiting the in vivo type 1 acute hypersensitivity reaction. In people, animal models, and isolated tissues, it has demonstrated antihistaminic properties. Olopatadine mediates anti-histaminic effects for five to 24 hours after injection. Its quick start and sustained endurance are noteworthy. On the other hand, some patients have experienced somnolence and transient blurred vision. It has little action on alpha-adrenergic, dopamine, muscarinic type 1 and 2, and serotonin receptors.

• Mechanism of Action: Olopatadine is an H1 antagonist and a mast cell stabilizer. It has also been shown that eosinophil activation is inhibited and that chemotaxis is reduced.

• Pharmacokinetics: The topical ocular solution Olopatadine had minimal systemic exposure following topical treatment. In two investigations, normal volunteers were given bilateral doses of Olopatadine 0.15 percent ophthalmic solution once every 12 hours for two weeks. The results showed that the plasma concentrations were mostly below the assay's quantitation limit, which is less than 0.5 ng/mL (nanogram per milliliter). Investigations revealed plasma quantities below the assay's quantitation limit. Within two hours of dosage, quantifiable samples ranging in concentration from 0.5 to 1.3 ng/mL were discovered. Following oral administration, the elimination half-life in plasma was eight to 12 hours, with renal excretion being the primary mode of elimination. Urine contained the parent substance in amounts between 60 and 70 percent of the dose. Low amounts of two metabolites were found in the urine: mono-desmethyl and N-oxide.The elimination half-life (plasma) is 3.4 hours (approximately).

NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, and Impairment of Fertility:

Oral administration of Olopatadine did not cause cancer in animals at doses up to 200 mg/kg/day (milligrams per kilogram per day) and 500 mg/kg/day, respectively. These dosages were roughly 150,000 and 50,000 times greater than the maximum recommended ocular human dose (MROHD), based on a 40 μL (microliters) drop size and a 110-pound individual. In vitro bacterial reverse mutation (Ames) test, in vitro mammalian chromosome aberration assay, and in vivo mouse micronucleus test results did not reveal any mutagenic potential for Olopatadine.

When Olopatadine was given orally to male and female rats at dosages roughly 100,000 times the MROHD level, the fertility index and implantation rate decreased slightly; at doses roughly 15,000 times the MROHD, no effects on reproductive function were noted.

Drug Interactions

Although there are no known drug interactions with Olopatadine, it is still important to let the physician know about all of the prescription and over-the-counter medications, herbal supplements, vitamins, and other non-prescription medications.

Clinical Studies

• Clinical trials lasting up to 12 weeks indicate that a daily dosage of Olopatadine solution is effective in managing ocular irritation linked to allergic conjunctivitis.

• The study examined the efficacy of Alcaftadine 0.25 percent, Olopatadine 0.2 percent, and placebo (dextran 70 0.1 percent or hydroxypropyl methylcellulose 0.3 percent) in treating patients with acute allergic conjunctivitis. Each therapy was administered with one drop to each participant's eye. According to the study, Olopatadine 0.2 percent and Alcaftadine 0.25 percent effectively treated acute allergic conjunctivitis.

Specific Considerations

• Pregnancy: Due to limited animal research, Olopatadine should only be used in pregnant women if the possible benefit to the mother surpasses the possible risk to the embryo or fetus. It has been confirmed not to be teratogenic in animal studies.

• Breastfeeding: Use caution while providing 0.2 percent Olopatadine hydrochloride ophthalmic solution to humans. Olopatadine has been discovered in nursing rats' milk following oral administration, but its potential in human breast milk is unknown.

• Pediatric Use: Olopatadine's efficacy and safety in pediatric patients younger than two years old have not been established.

• Geriatric Use: Olopatadine's efficacy and safety in older versus younger patients are similar.